Article
Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
Neurosurgical focus - 1 Feb 2022
Richardson Leland G, Miller Julie J, Kitagawa Yosuke, Wakimoto Hiroaki, Choi Bryan D, Curry William T
Abstract excerpt
Immunotherapy has emerged as a promising approach for treating aggressive solid tumors, even within the CNS. Mutation in the metabolic gene isocitrate dehydrogenase 1 (IDH1) represents not only a major glioma defining biomarker but also an attractive therapeutic neoantigen. As patients with IDH-mutant glioma enter early-phase vaccine and immune checkpoint inhibitor clinical trials, there is emerging evidence that...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.